Sudeep Pharma Ltd. (SUDEEPPHRM) Share Price Hits Fresh 52-Week High
- July 29, 2026
- Posted by: Harsh Piplani
- Category: News
Sudeep Pharma Ltd. Share Price reached a fresh 52-week high of Rs 907.4, rising 4.66% today. The market cap stands at Rs 9,676.31 crore.
Sudeep Pharma Ltd. Share Price has surged to a fresh 52-week high of Rs 907.4, marking a significant rise of 4.66% today. The stock opened at Rs 862.15 and reached a low of Rs 850 before climbing to its new peak. With a market capitalisation of Rs 9,676.31 crore, Sudeep Pharma Ltd. is attracting attention in the healthcare sector. This milestone highlights the stock’s upward momentum, although the data does not specify a company-specific catalyst for this rise. Investors are closely monitoring the stock’s performance, given its recent achievements.
Sudeep Pharma Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 902.3 |
| Previous Close | Rs 862.15 |
| Today's Change | +Rs 40.15 (+4.66%) |
| Day Open | Rs 862.15 |
| Fresh 52-Week High | Rs 907.4 |
| Day Low | Rs 850 |
| Current Volume | 25,240 |
| Turnover | Rs 2.28 crore |
| Market Capitalisation | Rs 9,676.31 crore |
Sudeep Pharma Ltd. (SUDEEPPHRM) traded at Rs 902.3. versus the previous close of Rs 862.15, a rise of 4.66%. The stock opened at Rs 862.15, reached Rs 907.4, touched Rs 850. Reported volume was 25,240.
Today, Sudeep Pharma Ltd. Share Price opened at Rs 862.15 and quickly gained traction, reaching a fresh 52-week high of Rs 907.4. The stock closed the previous day at Rs 862.15, and today’s increase of Rs 40.15 represents a 4.66% rise. The day’s low was Rs 850, and the turnover was Rs 2.28 crore with a volume of 25,240 shares. This price action indicates strong investor interest and momentum, setting the stage for further analysis of the stock’s fundamentals and sector positioning.
Sudeep Pharma Ltd. (SUDEEPPHRM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 9,676.31 crore |
| P/E Ratio | 29.31x |
| P/B Ratio | 0.43x |
| ROE | -2.89% |
| ROCE | -0.26% |
Sudeep Pharma Ltd. was valued at a P/E ratio of 29.31x, a P/B ratio of 0.43x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 29.31x |
| Benchmark Median P/E | 21.06x |
| Benchmark Average P/E | 68.59x |
| Benchmark P/E Range | 0x to 3,439.3x |
| Company P/B Ratio | 0.43x |
| Benchmark Median P/B | 1.88x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.91% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 9,676.31 crore |
| Benchmark Median Market Cap | Rs 140.64 crore |
Sudeep Pharma Ltd. (SUDEEPPHRM) is classified under sector: Healthcare.
Sudeep Pharma Ltd. (SUDEEPPHRM) has a P/E ratio of 29.31x, which is above the benchmark median of 21.06x, a difference of +39.17%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sudeep Pharma Ltd. (SUDEEPPHRM) has a ROE of -2.89%, which is below the benchmark median of 10.91%, a difference of -126.49%. Sudeep Pharma Ltd. (SUDEEPPHRM) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,921.65 | 29.31 | 0.43 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,815.27 | 39.89 | 8.12 | 28.21 | 26.35 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,476.69 | 169.37 | 3.13 | 13.9 | 12.97 |
| Beta Drugs Ltd. | BETA | 2,472.93 | 56.38 | 8.92 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,444.35 | 34.87 | 7.06 | -2.6 | 16.92 |
Sudeep Pharma Ltd. (SUDEEPPHRM) has a P/E ratio of 29.31x compared with the displayed peer median of 39.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Sudeep Pharma Ltd. (SUDEEPPHRM) has a market capitalisation of Rs 9,676.31 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Sudeep Pharma Ltd.
- Fresh 52-week high at Rs 907.4, indicating strong price momentum.
- Mixed valuation metrics with a low P/B ratio.
- Negative profitability metrics, raising concerns.
- Significant market capitalisation within the healthcare sector.
About Sudeep Pharma Ltd.
Sudeep Pharma Ltd. operates within the healthcare sector, focusing on pharmaceuticals and drugs. The company has established itself as a notable player, with a market capitalisation of Rs 9,676.31 crore. Despite its recent stock performance, the company faces challenges in profitability, as indicated by its negative ROE and ROCE. Sudeep Pharma Ltd. continues to navigate the competitive landscape of the healthcare industry, striving to enhance its financial performance and market position.
Track Sudeep Pharma Ltd. Share Price on Univest
Use Sudeep Pharma Ltd. (SUDEEPPHRM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Sudeep Pharma Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed about the latest developments and performance metrics.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Sudeep Pharma Ltd.?
Ans. The current share price of Sudeep Pharma Ltd. is Rs 902.3, marking a 4.66% increase from the previous close of Rs 862.15. The stock moved 4.66% during the session. The intraday range extended from Rs 850 to Rs 907.4.
What was the 52-week high for Sudeep Pharma Ltd.?
Ans. The 52-week high for Sudeep Pharma Ltd. is Rs 907.4, achieved today, reflecting strong price momentum in the market. The stock moved 4.66% during the session. The intraday range extended from Rs 850 to Rs 907.4.
How does Sudeep Pharma Ltd.'s P/E ratio compare to the sector?
Ans. Sudeep Pharma Ltd.'s P/E ratio of 29.31 is above the sector median of 21.06 but below the average of 68.59, indicating a mixed valuation. The company trades at a P/E ratio of 29.31x.
What is Sudeep Pharma Ltd.'s market capitalisation?
Ans. Sudeep Pharma Ltd. has a market capitalisation of Rs 9,676.31 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 29.31x.
What are Sudeep Pharma Ltd.'s profitability metrics?
Ans. Sudeep Pharma Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, indicating challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%.
How does Sudeep Pharma Ltd.'s P/B ratio compare to its peers?
Ans. Sudeep Pharma Ltd.'s P/B ratio of 0.43 is notably lower than its peers, suggesting potential undervaluation on this metric. The company trades at a P/E ratio of 29.31x. Its P/B ratio is 0.43x.
How does Sudeep Pharma Ltd.'s market cap compare to the sector median?
Ans. Sudeep Pharma Ltd.'s market cap of Rs 9,676.31 crore is significantly above the sector median of Rs 140.64 crore, highlighting its substantial presence. The company operates in the Healthcare sector.
